Details for Patent: 6,414,024
✉ Email this page to a colleague
Title: | GABA and L-glutamic acid analogs for antiseizure treatment |
Abstract: | A compound of the formula ##STR1## wherein R.sub.1 is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R.sub.2 is hydrogen or methyl; and R.sub.3 is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed. |
Inventor(s): | Silverman; Richard B. (Morton Grove, IL), Andruszkiewicz; Ryszard (Sopot, PL), Yuen; Po-Wai (Ann Arbor, MI), Sobieray; Denis Martin (Holland, MI), Franklin; Lloyd Charles (Hamilton, MI), Schwindt; Mark Alan (Holland, MI) |
Assignee: | Northwestern University (Evanston, IL) Warner-Lambert Company (Ann Arbor, MI) |
Filing Date: | Feb 04, 1999 |
Application Number: | 09/244,700 |
Claims: | 1. A method of treating a patient having Huntington's Disease which includes administering to the patient an anti-seizure effective amount of a compound selected from the following formula: ##STR12## wherein R.sub.11 is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R.sub.12 is hydrogen or methyl; and R.sub.13 is hydrogen, methyl, or carboxyl; individual enantiomers thereof; and pharmaceutically acceptable salts thereof. 2. The method of claim 1 wherein R.sub.11 is a straight or branched alkyl group having from 1 to 6 carbon atoms. 3. The method of claim 1 wherein the alkyl group has 4 carbon atoms. 4. The method of claims 1 wherein R.sub.11 is isobutyl. 5. The method of claim 1 wherein R.sub.13 is hydrogen. 6. The method of claim 1 wherein R.sub.12 is hydrogen. 7. A method of treating a patient having Huntington's Disease which includes administering to a patient an anti-seizure effective amount of the compounds 4-amino-3-(2-methylpropyl)butanoic acid. 8. A method a treating a patient having Huntington's Disease which includes administering to a patient an anti-seizure effective amount of the compound S-(+)4-amino-3-(2-methylpropyl)butanoic acid. |